MLANA and neoplasm: This early study showed evidence of clinical activity in only 2 out of 17 patients but a more recent report by Chodon et al. (231) demonstrated that MART-1 specific T cells in combination with MART-1 pulsed DC vaccine were able to induce tumor regression in 9 out of 13 studied patients (231).